Trial Profile
Oral topotecan utilization for a metronomic dosing schedule to treat recurrent or persistent solid tumors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 17 Jul 2013 Primay endpoint amended as reported by ClinicalTrials.gov.
- 06 Jul 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 06 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.